Concepedia

Vaishali Bhosekar

VB

Statistics

Publications

3

Citations

463

H-Index

3

Active since

2017

Affiliations

Novartis (Switzerland)(Current)

Novartis (India)

Vaishali Bhosekar is an author at Novartis (Switzerland) specializing in medicine, pharmacotherapy, and inflammation.

Publications per year

2017–2019

3

Publications

3

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial

Bernard Zinman, Vaishali Bhosekar, Robert S. Busch et al. · The Lancet Diabetes & Endocrinology · 2019 · 367 citations

Medicine, Pharmacology, Pharmacotherapy +13

Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies

Andreas Körber, C. Papavassilis, Vaishali Bhosekar et al. · Drugs & Aging · 2018 · 66 citations · Full text

Medicine, Dermatology, Pharmacotherapy +15

Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52‐week pooled results from two phase 3 studies

James Cheng‐Chung Wei, Dominique Baeten, Joachim Sieper et al. · International Journal of Rheumatic Diseases · 2017 · 30 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

1–3 of 3